Display options
Cite
Corcione S, De Nicolò A, Montrucchio G, et al. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. Br J Clin Pharmacol. 2021;87(12):4861-4867doi: 10.1111/bcp.14895.
Corcione, S., De Nicolò, A., Montrucchio, G., Scabini, S., Avataneo, V., Bonetto, C., Mornese Pinna, S., Cusato, J., Canta, F., Urbino, R., Di Perri, G., Brazzi, L., De Rosa, F. G., & D'Avolio, A. (2021). Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. British journal of clinical pharmacology, 87(12), 4861-4867. https://doi.org/10.1111/bcp.14895
Corcione, Silvia, et al. "Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia." British journal of clinical pharmacology vol. 87,12 (2021): 4861-4867. doi: https://doi.org/10.1111/bcp.14895
Corcione S, De Nicolò A, Montrucchio G, Scabini S, Avataneo V, Bonetto C, Mornese Pinna S, Cusato J, Canta F, Urbino R, Di Perri G, Brazzi L, De Rosa FG, D'Avolio A. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. Br J Clin Pharmacol. 2021 Dec;87(12):4861-4867. doi: 10.1111/bcp.14895. Epub 2021 Jul 04. PMID: 33990984; PMCID: PMC8239594.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 2021 Dec;87(12):4861-4867. doi: 10.1111/bcp.14895. Epub 2021 Jul 04.

Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.

British journal of clinical pharmacology

Silvia Corcione, Amedeo De Nicolò, Giorgia Montrucchio, Silvia Scabini, Valeria Avataneo, Chiara Bonetto, Simone Mornese Pinna, Jessica Cusato, Francesca Canta, Rosario Urbino, Giovanni Di Perri, Luca Brazzi, Francesco Giuseppe De Rosa, Antonio D'Avolio

Affiliations

  1. Department of Medical Sciences, Infectious Diseases, University of Turin, Italy.
  2. Tufts School of Medicine, Boston, MA, USA.
  3. Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Italy.
  4. Department of Surgical Sciences, University of Turin, Italy.

PMID: 33990984 PMCID: PMC8239594 DOI: 10.1111/bcp.14895

Abstract

Remdesivir is one of the most encouraging treatments against SARS-CoV-2 infection. After intravenous infusion, RDV is rapidly metabolized (t

© 2021 British Pharmacological Society.

Keywords: COVID-19; ICU; SARS-CoV-2; pharmacokinetics; pneumonia; remdesivir

References

  1. Lupia T, Scabini S, Mornese Pinna S, di Perri G, de Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCo) outbreak: a new challenge. J Glob Antimicrob Resist. 2020;21:22-27. - PubMed
  2. Osho AA, Moonsamy P, Hibbert KA, et al. Veno-venous extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: early experience from a major academic medical center in North America. Ann Surg. 2020;272(2):e75-e78. - PubMed
  3. Barbaro RP, MacLaren G, Boonstra PS, et al. for the Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020;396(10257):1071-1078. - PubMed
  4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed May 20, 2021. - PubMed
  5. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed May 20, 2021. - PubMed
  6. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19-interim WHO Solidarity Trial results. N Engl J Med. 2021;384:497-511. - PubMed
  7. De Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12):6771-6776. - PubMed
  8. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):1-12, eaal3653. - PubMed
  9. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303. - PubMed
  10. European Medicines Agency. Summary on compassionate use: Remdesivir Gilead. April 3, 2020. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf. Accessed May 20, 2021. - PubMed
  11. Jiang Y, Chen D, Cai D, Yi Y, Jiang S. Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: a network meta-analysis. J Med Virol. 2021;93(2):1171-1174. - PubMed
  12. Lai CC, Chen CH, Wang CY, Chen KH, Wang YH, Hsueh PR. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;dkab093. mar(24):1-7. - PubMed
  13. Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy. 2020;40(7):659-671. - PubMed
  14. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-385. - PubMed
  15. Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021;60(5):569-583. - PubMed
  16. Avataneo V, de Nicolò A, Cusato J, et al. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. J Antimicrob Chemother. 2020;75(7):1772-1777. - PubMed
  17. Beigel JH, Tomashek KM, Dodd LE, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383(19):1813-1826. - PubMed
  18. Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158(104899):1043-6618, 104899. - PubMed
  19. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-2336. - PubMed
  20. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;1-13, 10. https://doi.org/10.1093/cid/ciaa478 - PubMed
  21. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. Pharmacol Res. 2020;58(10493):1-7, 104931. - PubMed
  22. Lê MP, Le Hingrat Q, Jaquet P, et al. Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19. Antimicrob Agents Chemother. 2020;64(11):1-4, e01521-20. - PubMed
  23. Corcione S, D'Avolio A, Allegra S, et al. Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. Int J Antimicrob Agents. 2017;49(6):784-785. - PubMed
  24. de Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013;41(6):590-591. - PubMed
  25. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. - PubMed
  26. Cusato J, De Nicolò A, Boglione L, et al. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. J Antimicrob Chemother. 2018;73(6):1659-1664. - PubMed
  27. Notari S, Tempestilli M, Fabbri G, et al. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1073:183-190. - PubMed
  28. Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018;32(6):761-765. - PubMed

Publication Types